Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum LDL cholesterol (LDL-C) levels by facilitating the degradation of the LDL receptor (LDLR) and is an attractive therapeutic target for hypercholesterolemia intervention. Herein, we generated a novel fully human antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Menglong, Lei, Gaoxin, Chen, Manman, Wang, Ke, Lv, Wenxiu, Zhang, Panpan, Hu, Tuo, Gao, Jie, Lu, Chenchen, Mei, Ying, Xu, Zhipan, Bai, Zhengli, Hu, Huajing, Jiang, Yiwei, Tan, Shuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921758/
https://www.ncbi.nlm.nih.gov/pubmed/33647772
http://dx.doi.org/10.1016/j.ebiom.2021.103250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921758/
https://www.ncbi.nlm.nih.gov/pubmed/33647772
http://dx.doi.org/10.1016/j.ebiom.2021.103250

Ejemplares similares